Skeletal muscle expression of adipose-specific phospholipase in peripheral artery disease.

Autor:	Parmer C; Department of Medicine, Stanford University Medical Center, Palo Alto, CA, USA., De Sousa-Coelho AL; Centre for Biomedical Research, Universidade do Algarve, Faro, Portugal., Cheng HS; Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA., Daher G; Research Division, Joslin Diabetes Center, and Harvard Medical School, Boston, MA, USA., Burkart A; Research Division, Joslin Diabetes Center, and Harvard Medical School, Boston, MA, USA., Dreyfuss JM; Research Division, Joslin Diabetes Center, and Harvard Medical School, Boston, MA, USA., Pan H; Research Division, Joslin Diabetes Center, and Harvard Medical School, Boston, MA, USA., Prenner JC; Department of Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, USA., Keilson JM; Emory School of Medicine, Atlanta, GA, USA., Pande R; Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA., Henkin S; Heart and Vascular Center, Dartmouth-Hitchcock Medical Center and Geisel School of Medicine at Dartmouth, Lebanon, NH, USA., Feinberg MW; Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA., Patti ME; Research Division, Joslin Diabetes Center, and Harvard Medical School, Boston, MA, USA., Creager MA; Heart and Vascular Center, Dartmouth-Hitchcock Medical Center and Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
Jazyk:	angličtina
Zdroj:	Vascular medicine (London, England) [Vasc Med] 2020 Oct; Vol. 25 (5), pp. 401-410. Date of Electronic Publication: 2020 Aug 27.
DOI:	10.1177/1358863X20947467
Abstrakt:	Flow-limiting atherosclerotic lesions of arteries supplying the limbs are a cause of symptoms in patients with peripheral artery disease (PAD). Musculoskeletal metabolic factors also contribute to the pathophysiology of claudication, which is manifest as leg discomfort that impairs walking capacity. Accordingly, we conducted a case-control study to determine whether skeletal muscle metabolic gene expression is altered in PAD. Calf skeletal muscle gene expression of patients with PAD and healthy subjects was analyzed using microarrays. The top-ranking gene differentially expressed between PAD and controls (FDR < 0.001) was PLA2G16 , which encodes adipose-specific phospholipase A2 (AdPLA) and is implicated in the maintenance of insulin sensitivity and regulation of lipid metabolism. Differential expression was confirmed by qRT-PCR; PLA2G16 was downregulated by 68% in patients with PAD ( p < 0.001). Expression of Pla2g16 was then measured in control (db/+) and diabetic (db/db) mice that underwent unilateral femoral artery ligation. There was significantly reduced expression of Pla2g16 in the ischemic leg of both control and diabetic mice (by 51%), with significantly greater magnitude of reduction in the diabetic mice (by 79%). We conclude that AdPLA is downregulated in humans with PAD and in mice with hindlimb ischemia. Reduced AdPLA may contribute to impaired walking capacity in patients with PAD via its effects on skeletal muscle metabolism. Further studies are needed to fully characterize the role of AdPLA in PAD and to investigate its potential as a therapeutic target for alleviating symptoms of claudication.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu